Solar Pharmaceutical Industries Restricted introduced, that certainly one of its wholly-owned subsidiaries has launched a novel anti-cancer drug, Palbociclib in India for sufferers who’ve superior breast most cancers, the commonest most cancers amongst ladies within the nation, through an trade submitting.

The corporate will make the drug obtainable below the model title, PALENO (Palbociclib) 75 mg, 100 mg, 125 mg.

Palbociclib is authorized by the USFDA, EMA and CDSCO together with hormonal therapies for sufferers with hormone receptor optimistic, human epidermal progress issue receptor 2 unfavourable domestically superior or metastatic breast most cancers.

Kirti Ganorkar, CEO– India Enterprise, Solar Pharma, stated “We’re introducing Palbociclib at an reasonably priced value which can assist enhance affected person entry. PALENO will deal with the remedy want of a number of superior breast most cancers sufferers in India. For the primary time, we’re introducing a singular affected person help program that may enhance affected person compliance and accessibility.”